Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00501618 · ClinicalTrials.gov registry record · Phase 4

Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder

A Phase 4 study, sponsored by Manhattan Psychiatric Center.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target

NCT00501618 is a Phase 4 study that has completed, run by Manhattan Psychiatric Center. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00501618, a Phase 4 study, has completed, sponsored by Manhattan Psychiatric Center.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to obtain data on equivalence of generic clozapine to Fazaclo (orally disintegrating tablet). Generic clozapine is the most frequently used clozapine and such data is important for clinicians to have.

Interventions

  • DRUG Fazaclo

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2006-11
Est. Completion 2009-07
Phase Phase 4

Sponsor

Manhattan Psychiatric Center

7 total trials

What the Registry Record Tells You About NCT00501618

The ClinicalTrials.gov registry entry for NCT00501618 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Manhattan Psychiatric Center, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Fazaclo is the first listed.

NCT00501618 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00501618 about?

NCT00501618 is a clinical study titled "Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder". The purpose of this study is to obtain data on equivalence of generic clozapine to Fazaclo (orally disintegrating tablet). Generic clozapine is the most frequently used clozapine and such data is important for clinicians to have.

What is the current status of trial NCT00501618?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2006-11. Estimated completion is 2009-07.

What interventions are being tested in trial NCT00501618?

The interventions under investigation include: Fazaclo (DRUG).

Who is sponsoring clinical trial NCT00501618?

This trial is sponsored by Manhattan Psychiatric Center, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.